Santhera expands Biomedica distribution deal to bring AGAMREE vamorolone to Central Asia and the Caucasus
Executive summary: Santhera Pharmaceuticals announced an expansion of its exclusive distribution agreement with Biomedica to include AGAMREE (vamorolone) in Georgia, Kazakhstan, Belarus, Azerbaijan, and Uzbekistan. The extension opens new revenue streams in underserved Central Asian and Caucasian markets and strengthens Santhera's international footprint for a niche corticosteroid.
Who is involved: Santhera Pharmaceuticals (SIX: SANN), Biomedica (distribution partner), and regulatory authorities in the five target countries.
Likely next: Biomedica will initiate local regulatory submissions and launch distribution channels, with Santhera expected to report sales impact in its next quarterly earnings release.
Santhera Pharmaceuticals announced on July 13, 2026 an extension of its exclusive distribution agreement with Biomedica to cover Georgia, Kazakhstan, Belarus, Azerbaijan, and Uzbekistan for its glucocorticoid AGAMREE (vamorolone). The move broadens the drug's geographic reach in emerging markets where treatment options for Duchenne muscular dystrophy and other inflammatory conditions are limited. By leveraging Biomedica's regional network, Santhera aims to increase sales volume and market penetration while navigating varying regulatory pathways in each country.
Timeline
- — Santhera Expands Biomedica Agreement to Extend AGAMREE® (Vamorolone) Distribution Across Central Asia and the Caucasus (GlobeNewswire)
Analysis — what this means
Sectors affected
- Pharmaceuticals
- Central Asia healthcare market
- Caucasus healthcare market
Sources
Open the full interactive case file on Beyond →
INTELLIGENCE
Social Pulse
AI estimate · not scraped